<unk>  is a CD4-directed post-attachment HIV-1 inhibitor that is FDA approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.   Common adverse reactions include diarrhea, dizziness, nausea, and rash.
Ibalizumab
Risankizumab
Ocrelizumab
Reslizumab
Natalizumab
Efalizumab
Tocilizumab
Emicizumab